Improved Outlook for Myriad Genetics
We're raising our fair value estimate on the narrow-moat firm after the unveiling of a new cancer product.
We are raising our fair value estimate for narrow-moat
We view riskScore as the fourth generation of Myriad’s hereditary cancer products and believe it is a tactful use of Myriad’s proprietary database of cancer variations. Hereditary cancer testing can often lead to vague answers for a wide swath of patients, as fewer than 10% of women at risk of breast cancer carry a clinically actionable mutation. The new product evaluates a woman's risk of developing breast cancer by combining genetic markers throughout the genome with the patient’s family and clinical history. The score is a simple percentage risk of developing breast cancer for a given patient, which is compared with the risk of the overall population. We believe it will take time to gain momentum and could attract patients who are not necessarily utilizing myRisk now but want to understand if they need MRIs each year.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.